cardiovascular
diseas
cvd
lead
caus
mortal
worldwid
account
death
industrialis
societi
number
antiplatelet
therapi
current
approv
manag
patholog
thrombosi
includ
cyclooxygenas
cox
inhibitor
eg
aspirin
phosphodiesteras
pde
inhibitor
eg
cilostazol
irrevers
adp
receptor
antagonist
eg
clopidogrel
prasugrel
fibrinogen
receptor
block
antibodi
eg
abciximab
eptifibatid
current
antiplatelet
drug
mean
method
action
undesir
side
effect
includ
haemorrhag
gastrointestin
cerebr
neutropenia
headach
skin
irrit
hypertens
develop
new
antiplatelet
agent
especi
druglik
small
molecul
long
overdu
drug
repurpos
lowrisk
highgain
strategi
drug
discoveri
develop
drug
use
one
indic
repurpos
treat
anoth
approach
reduc
durat
cost
associ
risk
inher
tradit
drug
discoveri
drug
repurpos
well
truli
spotlight
major
focu
pharmaceut
industri
us
nation
institut
health
uk
medic
research
council
applic
comput
approach
drug
discoveri
eg
virtual
screen
silico
dock
greatli
increas
power
lead
identif
elucid
novel
chemic
scaffold
yet
despit
power
promis
silico
repurpos
approach
far
report
antiplatelet
agent
sensibl
place
identifi
new
target
develop
novel
therapi
physiolog
process
underli
diseas
success
antiplatelet
agent
date
aspirin
clopidogrel
work
directli
inhibit
enzym
receptor
mediat
secondari
phase
platelet
activ
howev
previous
mention
undesir
side
effect
inappropri
bleed
major
problem
current
antiplatelet
agent
new
target
could
yield
better
drug
improv
efficaci
reduc
side
effect
evid
suggest
inhibit
adhes
receptor
collagen
receptor
gpvi
von
willebrand
receptor
gpibixv
may
viabl
approach
reduc
patholog
thrombu
format
vivo
platelet
adher
expos
collagen
fibr
follow
injuri
vessel
wall
physiolog
respons
ruptur
atherosclerot
plaqu
patholog
respons
circul
von
willibrand
factor
vwf
complex
expos
collagen
fibr
togeth
protein
act
ligand
platelet
adhesionactiv
receptor
gpibixv
complex
glycoprotein
gp
vi
adhes
via
gpibixv
mediat
platelet
roll
tether
allow
major
platelet
collagen
receptor
gpvi
interact
ligand
mediat
platelet
activ
engag
gpvi
initi
tyrosin
kinasedepend
signal
via
associ
chain
contain
immunoreceptor
tyrosinebas
activ
motif
itam
releas
subsequ
granul
secret
lead
releas
secondari
mediat
platelet
activ
includ
adp
act
autocrin
fashion
concurr
event
gener
thrombin
fibrinogen
lead
format
fibrin
clot
mani
mediat
platelet
activ
could
target
drug
develop
gpvi
activ
earli
event
collageninduc
thrombu
format
receiv
increas
attent
potenti
target
antiplatelet
develop
recent
characteris
gpvifc
fusion
protein
block
plateletcollagen
interact
well
develop
humanis
murin
gpvi
scfv
highlight
gpvi
therapeut
target
gpvifc
fusion
protein
inhibit
collagen
respons
anim
model
demonstr
lack
toxic
human
trial
bleed
phenotyp
effect
biolog
reduc
thrombosi
reminisc
endogen
mechan
regul
gpvicollagen
interact
receptor
shed
high
shear
data
strengthen
argument
target
collagengpvi
interact
therapeut
intervent
howev
administr
scfv
antibodi
fusion
protein
reli
intraven
inject
therefor
viabl
approach
selfadministr
longterm
use
outsid
clinic
especi
highli
preval
diseas
develop
oral
bioavail
small
druglik
gpvispecif
antagonist
could
therefor
great
therapeut
valu
would
provid
altern
option
manag
thrombot
risk
studi
describ
identif
characteris
two
select
gpvi
receptor
antagonist
vitro
antiphosphotyrosin
monoclon
antibodi
purchas
millipor
upstat
uk
losartan
cinanserin
purchas
tocri
bioscienc
bristol
uk
reagent
purchas
sigma
pool
uk
nih
clinic
collect
purchas
evotec
ca
us
inc
crystal
structur
human
platelet
glycoprotein
vi
pdb
id
use
silico
dock
receptor
process
addit
proton
flip
gln
asn
use
molprob
receptor
process
use
program
fred
receptor
requir
hbond
ly
compound
set
dock
perform
use
fred
databas
compound
conform
pregener
use
omega
molecul
dock
score
fred
default
consensu
score
top
molecul
test
biolog
efficaci
use
crpxlinduc
releas
assay
whole
blood
taken
healthi
volunt
follow
written
consent
collect
ml
syring
contain
ml
sodium
citrat
accord
procedur
approv
local
research
ethic
committe
milton
keyn
ref
plateletrich
plasma
prp
isol
centrifug
minut
room
temperatur
prp
pool
ad
centrifug
minut
room
temperatur
platelet
resuspend
tyrod
buffer
mm
nacl
mm
mm
kcl
mm
mm
acid
hepe
mm
glucos
mm
ph
prewarm
acd
volum
adjust
ml
tyrod
buffer
follow
addit
ml
acd
cell
centrifug
minut
room
temperatur
result
cell
pellet
resuspend
prewarm
tyrod
buffer
final
cell
densiti
cellsml
aggreg
cellsml
peptid
pull
down
appropri
mm
ethylen
glycol
tetraacet
acid
egta
indomethacin
uml
apyras
ad
inhibit
platelet
aggreg
refer
nonaggreg
condit
platelet
stimul
agonist
final
volum
continu
stir
rpm
optic
aggregomet
drug
studi
platelet
incub
losartan
cinanserin
time
agonist
ad
aggreg
monitor
use
softwar
chronolog
corp
pennsylvania
usa
wash
human
platelet
incub
hour
wash
tyrod
buffer
resuspend
cellsml
chang
fluoresc
measur
bmg
fluostar
optima
plate
reader
use
excit
wavelength
nm
nm
calcul
use
follow
formula
kd
rmin
rmax
sfb
kd
bind
nm
r
ratio
rmax
ratio
condit
rmin
ratio
condit
sfb
ratio
baselin
fluoresc
nm
bound
condit
drug
studi
compound
preincub
platelet
minut
orbit
shake
addit
agonist
sampl
boil
laemmli
buffer
work
concentr
mm
trishcl
ph
mm
dithiothreitol
dtt
sodium
dodecyl
sulfat
sd
bromophenol
blue
glycerol
protein
resolv
nupag
precast
trisglycin
gel
invitrogen
uk
prior
transfer
onto
nitrocellulos
per
gel
min
membran
block
nonfat
milk
powdertrisbuff
tbst
mm
tri
mm
nacl
gentl
agit
one
hour
room
temperatur
rt
overnight
primari
antibodi
ad
membran
appropri
dilut
marveltbst
gentl
agit
h
rt
overnight
membran
wash
time
tbst
minut
appropri
hrpconjug
secondari
antibodi
dako
ad
membran
nonfat
milk
powdertbst
incub
room
temperatur
min
gentl
agit
membran
wash
time
tbst
min
band
visualis
ecl
plu
detect
reagent
ge
lifesci
littl
chalfont
uk
use
agfa
curix
develop
whole
blood
incub
pe
conjug
antibodi
bd
bioscienc
uk
fluorescein
isothiocyan
fitc
fibrinogen
dako
eli
uk
drug
agonist
final
volum
tyrodeshep
buffer
crpxl
ad
final
concentr
incub
room
temperatur
minut
sampl
fix
ml
formyl
salin
steril
filter
exposur
pselectin
fitcfibrinogen
bind
measur
use
bd
accuri
flow
cytomet
gpvi
level
whole
blood
incub
drug
minut
room
temperatur
antigpvi
antibodi
gpvi
ml
kahn
univers
pennsylvannia
mgml
ad
incub
min
room
temperatur
donkey
antimous
antibodi
conjug
alexa
fluor
ad
sampl
incub
room
temperatur
minut
sampl
fix
ml
formyl
salin
steril
filter
read
bd
accuri
flow
cytomet
librari
fdaapprov
drug
diastereom
dock
gpvi
ligand
bind
site
emphasi
electrostat
environ
posit
figur
lie
within
floor
groov
form
collagen
bind
site
gpvi
compound
rank
abil
bind
region
use
singl
point
screen
releas
high
dose
drug
high
dose
crosslink
collagen
relat
peptid
crpxl
found
dock
yield
high
success
rate
top
compound
inhibit
crpxlinduc
releas
wash
human
platelet
figur
use
light
transmiss
aggregometri
limit
point
dilut
seri
nm
rescreen
drug
demonstr
inhibit
releas
commerci
avail
identifi
gave
concentrationdepend
inhibit
gpvimedi
aggreg
figur
drug
fals
posit
eg
altanserin
pirenpiron
figur
j
other
show
weak
antagon
eg
zaleplon
deoxyadenosin
figur
h
cinanserin
losartan
demonstr
concentrationdepend
inhibit
suitabl
valu
figur
f
therefor
select
investig
cinanserin
figur
highest
rank
hit
dock
preliminari
experi
indic
micromolar
rang
angiotensin
ii
type
receptor
antagonist
losartan
figur
also
rank
highli
potenti
antagonist
retrospect
literatur
search
reveal
compound
previous
report
interact
collagen
bind
pocket
gpvi
inhibit
platelet
aggreg
vitro
vivo
fact
losartan
shown
interact
gpvi
collagen
bind
site
independ
studi
valid
methodolog
provid
confid
dock
paramet
appropri
losartan
includ
subsequ
experi
serv
posit
control
also
potenti
drug
repurpos
found
select
efficaci
losartan
welltoler
drug
cinanserin
also
includ
characteris
rank
greatest
probabl
interact
gpvi
exhibit
robust
inhibit
releas
fig
high
success
rate
comput
screen
compound
inhibit
crpxlinduc
releas
vitro
valid
use
silico
dock
strategi
identifi
potenti
receptor
antagonist
next
conduct
detail
studi
determin
precis
valu
losartan
cinanserin
use
platelet
function
assay
releas
induc
gpvispecif
agonist
crpxl
endogen
ligand
collagen
measur
quantifi
drug
inhibit
releas
concentrationdepend
manner
respons
crpxl
figur
collagen
figur
cinanserin
losartan
valu
micromolar
rang
losartan
valu
greater
cinanserin
determin
whether
inhibitori
effect
losartan
cinanserin
releas
could
translat
effect
gross
platelet
function
carri
light
transmiss
aggregometri
use
wash
human
platelet
drug
exhibit
dosedepend
inhibit
platelet
aggreg
respons
crpxl
figur
collagen
figur
valu
compar
releas
summaris
tabl
losartan
cinanserin
inhibit
crpxl
collageninduc
releas
aggreg
experiment
determin
select
compound
test
abil
antagonis
platelet
agonist
releas
aggreg
respons
receptor
agonist
agonist
thrombin
uml
presenc
absenc
drug
measur
losartan
cinanserin
minim
effect
platelet
activ
although
high
concentr
effect
observ
mesadpinduc
releas
figur
aggreg
figur
regard
thrombin
littl
effect
seen
releas
figur
aggreg
figur
engag
gpvi
ligand
induc
tyrosin
phosphoryl
associ
chain
conserv
tyrosin
residu
within
itam
src
famili
kinas
noncoval
associ
receptor
phosphoryl
lead
recruit
activ
tyrosin
kinas
syk
mediat
phosphoryl
number
downstream
target
lead
increas
global
tyrosin
phosphoryl
losartan
cinanserin
reduc
global
tyrosin
phosphoryl
induc
gpvispecif
agonist
crpxl
figur
endogen
ligand
collagen
effect
either
thrombin
global
tyrosin
phosphoryl
observ
figur
addit
incub
drug
prior
addit
crpxl
reduc
phosphoryl
chain
figur
indic
losartan
cinanserin
prevent
phosphoryl
itam
initi
phosphotyrosin
signal
follow
ligand
engag
recent
studi
pertain
antiplatelet
effect
losartan
focus
mainli
inhibit
thromboxan
receptor
tpr
signal
rather
collagen
platelet
rich
plasma
isol
mice
inject
losartan
mgkg
day
aggreg
respons
tpr
agonist
inhibit
inhibitori
effect
extend
thrombu
format
vivo
injuri
model
yet
studi
indic
losartan
thu
far
rel
select
gpvi
address
discrep
examin
effect
losartan
cinanserin
induc
platelet
aggreg
wash
human
platelet
losartan
figur
platelet
aggreg
compar
collagen
crpxl
tabl
result
indic
losartan
inhibit
compon
tp
receptor
signal
effect
gpvi
receptor
potent
cinanserin
effect
aggreg
figur
determin
rel
contribut
tpr
signal
inhibitori
effect
losartan
measur
pselectin
exposur
fitcfibrinogen
bind
whole
human
blood
presenc
absenc
tprspecif
antagonist
nm
cinanserin
includ
control
drug
effect
platelet
activ
figur
losartan
significantli
reduc
fitcfibrinogen
bind
pselectin
exposur
beyond
alon
figur
ad
compound
togeth
result
level
inhibit
similar
losartan
alon
cinanserin
also
significantli
reduc
fitcfibrinogen
bind
pselectin
exposur
compar
alon
figur
data
show
inhibitori
effect
losartan
gpvimedi
platelet
activ
due
sole
effect
tpr
addit
inhibitori
effect
crpxlinduc
platelet
activ
beyond
effect
tpr
similar
cinanserin
data
present
losartan
cinanserin
demonstr
select
inhibit
gpvimedi
platelet
activ
small
molecul
pharmacolog
agent
competit
mechan
action
prefer
set
determin
whether
antagonist
act
competit
manner
platelet
respons
crpxl
measur
rang
concentr
presenc
absenc
drug
figur
losartan
caus
rightward
shift
curv
compar
vehicl
alon
increas
valu
crpxl
n
p
minima
maxima
valu
equal
control
figur
indic
competit
bind
cinanserin
also
caus
rightward
shift
curv
increas
crpxl
n
p
suggest
also
act
competit
manner
figur
next
measur
level
gpvi
cell
surfac
flow
cytometri
experiment
verifi
inhibitori
effect
losartan
cinanserin
due
drugmedi
decreas
receptor
level
neither
drug
affect
gpvi
level
n
losartan
one
class
angiotensin
receptor
blocker
arb
also
includ
valsartan
olmesartan
amongst
other
valsartan
protect
effect
cardiovascular
outcom
report
losartan
vivo
suggest
inhibitori
effect
losartan
gpvi
may
uniqu
amongst
drug
class
structur
evid
support
three
sartan
compar
losartan
effect
gpvimedi
releas
determin
whether
gpvi
antagon
share
amongst
drug
class
losartan
potent
efficaci
inhibitor
collageninduc
releas
collagen
n
figur
activ
observ
prodrug
olmesartan
medoxomil
current
therapeut
strategi
manag
occurr
arteri
thrombosi
gener
reli
dual
antiplatelet
therapi
thienopyridin
aspirin
approach
costeffect
reduc
thrombot
risk
come
price
consider
number
patient
experienc
bleed
complic
genet
polymorph
also
reduc
effect
aspirin
thienopyridin
result
drug
resist
patient
gpvi
one
number
potenti
target
propos
develop
new
antiplatelet
agent
solubl
gpvifc
fragment
revacept
reduc
platelet
adhes
recruit
site
vascular
injuri
moder
effect
tail
bleed
time
mice
human
phase
clinic
trial
revacept
advers
effect
health
bleed
time
platelet
show
reduc
respons
collagen
adp
thrombin
ex
vivo
similar
observ
losartan
cinanserin
vitro
although
revacept
may
protect
patholog
thrombosi
administr
requir
recurr
intraven
inject
patient
selfadminist
home
addit
continu
administr
prolong
period
may
lead
gener
antibodi
host
immun
system
neutralis
fusion
protein
provis
oral
avail
small
molecul
drug
inhibit
gpvi
interact
expos
collagen
may
provid
new
clinic
rout
longterm
manag
recurr
arteri
thrombosi
find
drug
adopt
drug
repurpos
strategi
identifi
new
gpvi
receptor
antagonist
librari
fdaapprov
drug
use
unbias
approach
identifi
compound
demonstr
gpvi
antagon
select
valu
micromolar
rang
losartan
gener
fdaapprov
compound
treatment
hypertent
cinanserin
receptor
antagonist
although
use
clinic
practic
decad
recent
attract
attent
inhibitor
sar
coronoaviru
replic
neither
compound
associ
bleed
complic
retrospect
report
effect
platelet
function
addit
losartan
shown
interact
gpvi
collagen
bind
site
ataround
nmr
due
previou
observ
losartan
affect
tpr
signal
look
effect
tprmediat
platelet
activ
agonist
losartan
inhibit
tpr
signal
valu
higher
gpvi
addit
losartan
cinanserin
reduc
fitcfibrinogen
bind
pselectin
exposur
respons
crpxl
tpr
inhibit
inhibit
much
greater
alon
demonstr
losartan
cinanserin
effect
crpxlinduc
platelet
aggreg
attribut
tpr
therefor
reason
say
base
studi
losartan
specif
gpvi
display
select
receptor
wash
human
platelet
whole
blood
experi
drug
lack
total
specif
hit
one
target
case
target
gpvi
tp
receptor
may
actual
prove
benefici
term
antiplatelet
activ
inde
tp
receptor
antagonist
terutroban
show
promis
antiplatelet
phase
ii
clinic
trial
found
offer
advantag
aspirin
regard
bleed
risk
cinanserin
appear
select
gpvi
losartan
high
unlik
reach
therapeut
level
blood
may
serv
start
point
futur
drug
design
term
drug
repurpos
viabl
candid
losartan
may
hold
promis
term
immedi
clinic
applic
antiplatelet
agent
welltoler
antihypertens
undergo
convers
metabolit
potent
parent
drug
compound
act
atii
type
receptor
antagonis
atiimedi
effect
vivo
recent
studi
demonstr
mice
administ
daili
inject
losartan
day
exhibit
reduc
platelet
aggreg
respons
ex
vivo
implic
losartan
tp
receptor
antagonist
mice
also
demonstr
reduc
thrombu
format
vivo
patholog
tail
bleed
time
physiolog
interest
note
vivo
outcom
similar
revacept
solubl
gpvifc
fragment
also
reduc
thrombu
format
vivo
minim
effect
physiolog
bleed
respons
howev
author
studi
examin
crpxl
collageninduc
signal
antagonist
effect
gpvi
signal
losartan
appear
uniqu
amongst
sartan
drug
class
activ
seen
prodrug
olmesartan
medoxomil
rapid
convers
activ
form
olmesartan
antagonis
gpvimedi
releas
unlik
exert
gpvi
antagon
vivo
like
antiplatelet
effect
losartan
attribut
inhibit
gpvi
tp
signal
data
losartan
intervent
endpoint
reduct
life
followup
studi
link
losartan
reduct
cardiovascular
mortal
stroke
myocardi
infarct
improv
clinic
outcom
author
life
studi
state
losartan
seem
benefit
beyond
blood
pressur
reduct
tempt
specul
could
due
antiplatelet
effect
similar
studi
valsartan
valu
show
effect
cardiovascular
outcom
may
due
fact
valsartan
antiplatelet
properti
gpvi
antagon
losartan
regard
whether
losartan
like
reach
plasma
concentr
high
enough
elicit
antiplatelet
effect
vivo
adult
given
mg
losartan
daili
day
cmax
valu
parent
drug
metabolit
ngml
ngml
respect
equat
plasma
concentr
around
nm
losartan
crp
collagen
induc
platelet
aggreg
releas
around
concentr
nm
losartan
give
around
inhibit
platelet
respons
gpvi
agonist
hand
losartan
given
dose
mg
per
day
quit
possibl
certainli
higher
dose
plasma
level
reach
concentr
high
enough
reduc
platelet
respons
collagen
losartan
alreadi
known
convey
rel
risk
reduct
stroke
compar
nonarb
antihypertens
agent
atenolol
aspirin
although
gold
standard
antiplatelet
therapi
actual
associ
slight
increas
risk
haemorrhag
stroke
losartan
therefor
efficaci
aspirin
prevent
stroke
report
bleed
effect
associ
clinic
use
also
gener
drug
therefor
cost
effect
losartan
arb
ace
inhibitor
shown
improv
outcom
alzheim
diseas
patient
improv
cerebr
blood
flow
reduc
inflammatori
respons
appear
losartan
could
offer
broad
rang
health
benefit
increasingli
age
popul
work
describ
herein
support
hypothesi
perturb
gpvicollagen
interact
small
molecul
inhibit
platelet
aggreg
lend
consider
weight
argument
develop
antiplatelet
drug
summari
report
identif
two
gpviselect
antagonist
may
serv
basi
futur
drug
design
cinanserin
repurpos
losartan
work
requir
determin
efficaci
losartan
bone
fide
gpvi
inhibitor
vivo
studi
set
scene
new
wave
antiplatelet
agent
target
gpvi
offer
new
strategi
manag
cardiovascular
risk
